SLU-PP-332
An ERRα agonist that mimics the metabolic effects of exercise without the actual exercise.
Common Dosage
Research phase
Category
Metabolic
- Endurance increase
- Fat oxidation
- Metabolic health
SLU-PP-332 was developed at Saint Louis University as part of research into estrogen-related receptor alpha (ERRα) signaling — a transcription factor that regulates mitochondrial biogenesis, fatty acid oxidation, and aerobic metabolism. ERRα activity mimics many of the gene expression changes triggered by endurance exercise. Researchers identified SLU-PP-332 as a potent ERRα agonist and have been investigating it as an 'exercise pill' — a compound that could deliver metabolic benefits of exercise to those unable to exercise due to disease or disability.
SLU-PP-332 activates ERRα, driving expression of genes involved in mitochondrial biogenesis (PGC-1α targets), fatty acid oxidation, and oxidative phosphorylation. This essentially upregulates the cellular machinery for aerobic energy production — increasing mitochondrial density and fat-burning capacity in muscle and other tissues, mimicking the metabolic adaptation of regular endurance training.
- Endurance capacity improvement without exercise
- Obesity and metabolic syndrome management
- Heart failure exercise intolerance research
- Mitochondrial disease supportive therapy
- Aging-related metabolic decline
Animal Endurance Enhancement
Rodent studies have demonstrated 50%+ improvements in running endurance in SLU-PP-332-treated animals compared to controls — without any exercise training. The mechanism involves increased muscle mitochondrial content and enhanced fat oxidation capacity, consistent with ERRα's target gene profile.
- Human data does not yet exist — this is purely preclinical
- ERRα has broad regulatory roles including in cancer biology — prostate cancer cells overexpress ERRα for energy metabolism; agonism could theoretically support tumor growth
- Long-term effects on skeletal muscle composition and cardiac function unknown
- Research compound with no quality control standards in the peptide market
- Unknown (Research)